Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 8:30 PM — Educational Meeting
Meeting Room
Continental Room B (Lobby Level)
No registration fee is charged for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.
Faculty Brian M Slomovitz, MD
Professor, OB-GYN, Florida International University
Director, Gynecologic Oncology
Co-Chair, Cancer Research Committee
Mount Sinai Medical Center
Miami, Florida
Additional faculty to be announced.
Moderator Shannon N Westin, MD, MPH, FASCO, FACOG
Professor
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
This activity is supported by educational grants from Eisai Inc, Gilead Sciences Inc, GSK, Karyopharm Therapeutics, and Merck.
Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 8:30 PM — Educational Meeting
MODULE 1: Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC)
Histologic subtypes and major molecular subgroups of EC; implications for prognosis and therapeutic decision-making
Optimal approaches to biomarker testing for patients with newly diagnosed advanced EC; implications of biomarker status for treatment decision-making
Similarities and differences in the designs and enrolled populations of the Phase III RUBY, NRG-GY018 and DUO-E trials evaluating the addition of dostarlimab, pembrolizumab and durvalumab, respectively, to platinum-based chemotherapy as first-line treatment for advanced or recurrent EC
Published efficacy and safety outcomes from the RUBY, NRG-GY018 and DUO-E trials
Antitumor activity observed with chemotherapy in combination with dostarlimab, pembrolizumab and durvalumab, respectively, in various patient subgroups —based on microsatellite instability (MSI)/mismatch repair (MMR) status, HER2 status, molecular subtype, et cetera — in the RUBY, NRG-GY018 and DUO-E trials
FDA approvals of dostarlimab and pembrolizumab in combination with chemotherapy for patients with advanced or recurrent EC regardless of MMR status; optimal incorporation into up-front therapy
Ongoing Phase III studies, such as DOMENICA and KEYNOTE-C93, evaluating first-line anti-PD-1/PD-L1 inhibitor monotherapy for MSI-high /MMR-deficient advanced or recurrent EC
MODULE 2: Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC
Rationale for the evaluation of PARP inhibition for advanced EC; possible therapeutic synergy between anti-PD-1/PD-L1 antibodies and PARP inhibitors
Key efficacy and safety findings from the Phase III RUBY Part 2 and DUO-E trials evaluating first-line chemoimmunotherapy followed by maintenance anti-PD-1/PD-L1 antibody with a PARP inhibitor for newly diagnosed advanced or recurrent EC
Outcomes with PARP inhibitors in various patient subsets of the RUBY Part 2 and DUO-E studies
Potential patient selection for and role of anti-PD-1/PD-L1 antibody/PARP inhibitor maintenance therapy for advanced EC
Long-term efficacy and safety findings from the Phase III KEYNOTE-775 trial comparing lenvatinib/pembrolizumab to chemotherapy for patients with advanced EC previously treated with a platinum-based regimen
Strategies to safely and effectively utilize pembrolizumab/lenvatinib; approaches to dosing and side-effect prevention and management
Current role of pembrolizumab/lenvatinib in EC management algorithms
MODULE 3: Promising Agents Under Investigation for EC: TROP2-Directed Antibody-Drug Conjugates (ADCs) and More
Biological rationale for the evaluation of TROP2-directed ADCs for advanced EC
Preliminary efficacy and safety findings reported with sacituzumab govitecan for patients with pretreated advanced EC
Design, eligibility criteria and primary and secondary endpoints of the ongoing Phase III ASCENT-GYN-01 trial evaluating sacituzumab govitecan versus treatment of physician’s choice for patients with EC who have experienced disease relapse after platinum-based chemotherapy and immunotherapy
Early efficacy outcomes documented with other TROP2-directed ADCs, such as datopotamab deruxtecan, sacituzumab tirumotecan
Other ongoing Phase III trials evaluating TROP2-directed ADCs
Mechanism of action of selinexor and biological rationale for its evaluation in EC, particularly for TP53 wild-type disease
Updated efficacy and safety findings with and ongoing Phase III evaluation of selinexor as maintenance therapy after first-line chemotherapy for patients with TP53 wild-type advanced or recurrent EC
Other promising agents and strategies under investigation for advanced EC
Target Audience
This activity is intended for medical and gynecologic oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of endometrial cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
Assess the clinical and biological characteristics of the various histologic subtypes and molecular subgroups of endometrial cancer (EC), and consider the implications for prognosis, biomarker evaluation and therapeutic decision-making.
Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and educate patients with microsatellite instability-high/mismatch repair (MMR)-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
Review available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic EC to receive this novel approach.
Recognize the biological rationale for the evaluation of trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugates for patients with EC, and consider available research findings with and potential of these agents.
Recognize adverse events associated with available and investigational therapies used in the treatment of EC to educate patients and manage complications.
Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.
FACULTY To be announced.
MODERATOR
To be announced.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters
This activity is supported by educational grants from Eisai Inc, Gilead Sciences Inc, GSK, Karyopharm Therapeutics, and Merck.
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400
Meeting Room
Continental Room B (Lobby Level)
Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.
This activity is intended for medical and gynecologic oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of endometrial cancer.
At this time in-person registration for this educational activity is limited to practicing clinicians actively caring for patients with cancer. For all other professionals, including industry personnel*, we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information by choosing the second registration option below. Should seats become available for the program, we will notify you.
No fee is charged to attend the session virtually.
NOTICE: Registration for this event is independent of registration for the 2026 ASCO Annual Meeting.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
STANDBY IN-PERSON Registration for other/industry professionals*
If you would like to stand by for participation in this event, please provide your contact information here. We will notify you if seats become available.
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
